Our purpose: Pharmacogenomic Tests
For MMJ and Rx Prescription Medications!
My purpose and passion in life is to help as many people as I can.
21 years ago, I started my own Venture Capital business, after serving as a professional President of 5 different companies. Over time I graduated to investments combining healthcare and technology….which has allowed me to help large numbers of people improve their health.
About 4 years ago, I was involved in deep due diligence to acquire a company in the Medical Cannabis industry. I learned about more about the positive results of people successfully utilizing Medical Cannabis to treat undesirable side effects so often created by Rx prescription medications as they also try to reduce their dependencies on prescription drugs.
My daughter-in-law Joy, a biomedical engineer, introduced me to the fantastic evidenced-based science of Pharmacogenomics (PGx).
My own PGx test results indicated I desperately needed to change the one single medication I was taking (for arthritis = old football player!). This test may have saved my life! (or at least my kidney’s!)
Next, we extensively explored the opportunity to use Pharmacogenomic Testing for the major cannabinoids that contribute to the many medical benefits of cannabis. We found that no such test existed! For the past 3 years we have engaged geneticists, researchers, and scientists who have dedicated their lives to Medical Cannabis.
Violâ….a true breakthrough! Our purpose-driven team created Navigator Genomics Testing™ to be the first company to measure your personal genetic metabolism, response and effectiveness for both the most popularly prescribed prescription medications (Rx) and for key cannabinoids used in Medical Cannabis (MMJ)….. Your test results will empower you & your healthcare professionals leading the way for you to receive truly personalized treatments and medications!
With So Many Blessings,
Founder & CEO
Travis Parr is the Founder of Navigator Genomics™ this unique pharmacogenomics lab testing business that measures one’s individual genes for best utilization choices for Prescription Medications & the key Cannabinoids used for Medical Cannabis.
He is President and Managing Director of Parr Enterprises, LLC, Private Venture Capital, founded in 1995, located in New Orleans, LA and Auburn Hills, MI. Parr Enterprises has a broad and diverse portfolio with emphasis on combining healthcare and innovative technology…… All meant to help as many people as possible with improving their health.
Mr. Parr was an early and active investor in China, providing growth capital to three Chinese companies, leading all three to go public on the NASDAQ, AMEX and Tokyo exchanges.
Formerly, Mr. Parr was lead investor and active participant with the executive team of Corphealth, Inc., an innovative behavioral healthcare company, that grew to a 54,000 physicians’ network serving over 4M people. Corphealth was sold to Humana in 2008.
His other past experiences include: President of Meteor Photo & Imaging Company, the USA’s second largest digital imaging company before selling this company to a UK public company; and as Executive Vice-President of American Tape Company, a $92 million privately-held manufacturer of pressure sensitive tapes and successfully selling the company to a $900M Korean–based conglomerate. Additionally, he served as Executive Vice-President, Allen Test Products, Inc., (artificial intelligence diagnostics software).
He began his career as the Marketing Manager of Chrysler Space Division, New Orleans, LA and was later promoted to Manager of Chrysler’s Electronics Division, Huntsville, AL. He has served as Chairman of the Board for several technology and healthcare businesses.
in 2014 Mr. Parr joined Satori Capital, a Private Equity firm based in Dallas & Fort Worth, as an Operating Partner. Satori’s core values of “Conscious Capitalism and Sustainability” aligned perfectly with Travis’ visions and values.
He is a 29-year member of the Young Presidents’ Organization (YPO) and YPO GOLD, an international organization comprised of 25,000 of the highest-level CEO’s & entrepreneurs around the world. Currently, he serves on the Executive Board, as Mentoring Officer and the Networks’ Officer for YPO Gold Louisiana. Mr. Parr was honored in 2015 as the ‘Network Man of the Year’ by YPO-WPO International.
Mr. Parr was awarded a full athletic scholarship (football) at Vanderbilt University. In 1974, he completed his Bachelor of Arts at Vanderbilt with a double major in Business & East Asian History. He earned an MBA from Emory University in 1977.
Mr. Parr resides in New Orleans, married to his beloved wife Peggy (38 years) and is an active member at Rayne Memorial United Methodist Church and enjoys teaching Sunday School and serving in various leadership roles… and walking their dog named “Gumbeaux”!Read More
Jahan Marcu, Ph.D.
Medical Cannabis Science Director
Dr. Marcu received his Doctorate for significant contributions to the study of the structure and function of cannabinoid receptors. Marcu’s published work in the prestigious journal, *Molecular Cancer Therapeutics*, includes studies on the anti-cancer effects of medical cannabinoids. Marcu is an author of the *American Herbal Pharmacopoeia’s Cannabis Inflorescence Monograph*, which has set the current US federal standards of identity, analysis and quality control for cannabis products. 15 years of experience in medical cannabis research, regulations, and advocacy. Dr. Marcu is also the Chief Auditor for Patient Focused Certification; Chief Scientist at Americans for Safe Access; and Co-Founder and R&D Director of Green Standard Diagnostics, Inc. He serves on multiple expert government, trade association committees, and scientific organizations including AHPA, ACS, AOCS, AOAC, ASA, IACM, IMCPC and others. His work has focused on the structure and function of cannabinoid receptors, the anti-cancer properties of cannabis compounds, Lou Gehrig's disease (ALS), as well as method development & validation for analyzing complex formulations. Dr. Marcu was the first recipient of the Billy Martin Research Award from the International Cannabinoid Research Society. He is also a court-qualified synthetic cannabinoid and cannabis expert.Read More
Michael Tagen Ph.D
Medical Cannabis & Pharmacology
Mike has a Ph.D. in Pharmacology and Experimental Therapeutics from Tufts University. He has the unique to the medical cannabis industry professional positions and invaluable experiences of working in academia, research, medical and clinical positions and worked in cutting-edge drug development business. Dr. Tagen has been peer-reviewed and published over 65 times, and serves as a frequent lecturer and independent consultant. He has been employed by leading institutions and organizations including Genetech, Bristol Myers Squibb, St. Jude's Research Hospital, and Tufts University. Dr. Tagen has won numerous highly prestigious BioMedical awards.Read More
Executive Vice President Business Development
Mr. Echegarrua is a proven leader with over 25 years’ experience in acquisitions, disposition, start ups and turn arounds in numerous companies throughout multiply business segments.
As President and CEO of a private equity firm, he lead a team that acquired, managed and ultimately disposed of over 100 million dollars in assets. -Before that and during the post Katrina era, Mr. Echegarrua’s entrepreneurial spirit drove him to importing building materials from all corners of the world which lead to assisting in reconstruction of more than 10,000 flood damaged structures in the New Orleans area.
Mr. Echegarrua has an MBA Freeman School of Business at Tulane University attending their Executive Program.
Chief Financial Officer
William Perez, JD, MBA, LL.M
Chief Legal Counsel
Administration & Customer Service
Scott Maloney is the CEO and Co-Founder of BowTie.io, where he’s focused on providing the fastest, most innovative application platform for entrepreneurs. His academic background and business experiences in Genetics has helped shape the mission and goals of our company. BowTie is an early partner of Navigator Genomics™ (“NGT”), assisting with e-commerce platform design, development, and support.
Prior to BowTie.io, Scott led teams and developed strategy for both startups and enterprise ventures, including @Pay, LivingSocial, Human Genome Sciences, and Pfizer. Scott is a geneticist by trade, holding a BS In genetics and cellular biology. Having spent time as an analyst at Pfizer, successfully published several academic papers focused on genetics research, and sold a small genetics bio-tech, he is an asset to assisting with NGT’s strategic direction.Read More